Microbot Medical Inc.
2.1900-0.20 (-8.37%)
Oct 28, 4:00:02 PM EDT · NasdaqCM · MBOT · USD
Key Stats
Market Cap
147.08MP/E (TTM)
-Basic EPS (TTM)
-0.58Dividend Yield
0%Recent Filings
8-K
Microbot secures logistics partner
Microbot Medical partnered with a U.S.-based third-party logistics firm to streamline commercialization of its FDA-cleared LIBERTY Endovascular Robotic System. This collaboration enables efficient inventory management and order processing from a climate-controlled warehouse near key markets. The company plans a limited market release in Q4 2025, followed by a broader launch in April 2026 at the Society of Interventional Radiology conference. Yet risks in commercialization persist.
8-K
Final closing nets $2.8M
Microbot Medical wrapped up its third and final closing on October 6, 2025, with a holder exercising preferred investment options for 1,324,488 common shares at $2.10 each, netting $2.8 million in gross proceeds before fees. This caps the overall exercise yielding $29.2 million across three closings, while issuing new short-term series J options for up to 1,324,488 shares at $4.50, potentially adding $63 million more if exercised. Funds will fuel LIBERTY Robotic System development and general corporate needs. Yet no guarantees on future exercises.
8-K
Microbot raises $29.2M via option exercises
Microbot Medical secured $25.2 million in gross proceeds from the first closing on September 16, 2025, where holders exercised existing preferred investment options for 12,064,627 common shares at prices from $1.50 to $2.13, receiving new Series J options for the same number at $4.50, exercisable after six months. A second closing by October 15, 2025, should add $4.0 million from 1,924,488 shares at $2.10. Funds will fuel LIBERTY Robotic System development and potential acquisitions, yet hinge on future option exercises amid regulatory risks.
8-K
Updated investor presentation released
Microbot Medical Inc. released updated presentation materials on September 9, 2025, under Regulation FD, accessible via its website and furnished as Exhibit 99.1. CEO Harel Gadot will present them live at the H.C. Wainwright Annual Investor Conference in New York that day at 9:00 a.m. ET. The company won't update these materials. No specific business impacts disclosed.
8-K
FDA clears LIBERTY robotic system
Microbot Medical secured FDA 510(k) clearance for its LIBERTY Endovascular Robotic System on September 8, 2025, marking the first single-use, remotely operated robotic tool for peripheral endovascular procedures. This greenlight enables U.S. commercialization in Q4 2025, targeting 2.5 million annual procedures while slashing physician radiation exposure by 92% and boosting efficiency. Pivotal study success was flawless. Yet commercialization hinges on securing more capital amid market risks.
IPO
Website
Employees
Sector
Industry
ANGO
AngioDynamics, Inc.
12.29+0.00
BSX
Boston Scientific Corporation
100.97-1.46
LMAT
LeMaitre Vascular, Inc.
89.54-0.58
MDNC
MEDINOTEC INC
5.00+0.00
MDT
Medtronic plc.
93.23-0.90
MGRM
Monogram Technologies Inc.
6.00+0.00
MMSI
Merit Medical Systems, Inc.
82.79+0.04
RBOT
Vicarious Surgical Inc.
5.75-0.10
SSII
SS Innovations International In
8.52-0.08
STXS
Stereotaxis, Inc.
2.97-0.08